Opinion|Videos|September 10, 2024

Closing

Fact checked by: Dean Elterman, MD, MSc

Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.

Episodes in this series

Video content above is prompted by the following:

  • How do minimally invasive surgical therapies (MIST) options fit into the evolving landscape of treatments for benign prostate dysplasia; why should urologists consider MIST options for their patients?
  • What unmet needs remain in the treatment of BPH, and are there any current trials/investigations in these topics?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more